No, companies will stop doing research now.
No, companies will stop doing research now.
"The first evidence for the existence of such a gene was provided by Mary-Claire King's laboratory at UC Berkeley in 1990. Four years later, after an international race to find it, the gene was cloned in 1994 by scientists at University of Utah, National Institute of Environmental Health Sciences (NIEHS) and Myriad Genetics."
Myriad Genetics are the sole licensee of the patent. They weren't solely responsible for it's discovery, or successful cloning.
From https://en.wikipedia.org/wiki/Myriad_Genetics#BRCA1_co-disco...:
>BRCA1 co-discoverers National Institute of Environmental Health Sciences (NIEHS) University of Utah Research Foundation Université Laval/Endo Research – Quebec The Hospital for Sick Children – University of Toronto University of Tokyo Myriad Genetics, Inc.
>BRCA2 co-discoverers University of Utah Research Foundation The Hospital for Sick Children – University of Toronto University of Pennsylvania Myriad Genetics, Inc.
The research was done by many organisations, not just "companies", and was done with no guarantee of profit. There are some researchers who are actually altruistic, and believe in medical progress to save lives.
With software patents, for instance, there may be no way to claim ownership of Algorithm X in a given jurisdiction's patent system, but there's probably no obstacle to claiming "A machine that executes Algorithm X." The problem then becomes tractable: just write the claims in such a manner that they cover all practical implementations of such a machine, present or future.
It will now be the job of the company's patent counsel to come up with a similar artifice to claim ownership of any conceivable test or diagnostic process that involves specific BRCA genes. I'm sure they'll pull it off, somehow.
Failing that, the company's lobbyists will simply ensure that the next regional or global trade agreement mandates that each ratifying nation implement gene patents.
That's what I'm worried about, too.
For example C60 [1] is a curious molecule that can't be patented anymore. In a rat study it showed to prolong the rats' lives by over 90% [2] by protecting the rats from cancer.
Sadly there won't be any human study anytime soon (if at all) because it's just not financially viable without the possibility of patenting the stuff and extracting fantasy prices for it.
[1] https://en.wikipedia.org/wiki/Buckminsterfullerene
[2] http://www.kurzweilai.net/fullerene-c60-administration-doubl...
Has anyone here access to the referenced paper [1] and can confirm that "Anthony Loera" worked on it?
[1] http://linkinghub.elsevier.com/retrieve/pii/S014296121200323...
Ref.: Baati T, et al., The prolongation of the lifespan of rats by repeated oral administration of [60]fullerene, Biomaterials (2012), doi:10.1016/j.biomaterials.2012.03.036
Lets also forget that passing drug test also grants additional state granted monopolies as a way to encourage just the very scenario stated above.
And if a company can not expect to have some exclusive rights on that for at least a few years no one is going to spend that money. Competitors could just take your medicine, copy it and sell for lower because they had no upfront costs of getting it approved.
The economics behind pharmaceuticals are perverted - but at least they work.
And even if all "cures" are no longer patentable - society wants cures to diseases. So if the system isn't delivering cures society will change the approval system[1]. It's not like the current approval process was handed down from god on stone tablets.
1) Or change patent law to cover discoveries from nature.
That's a use patent and it's inferior to a composition patent.
Look at what's happening to Pfizer in the UK. They had a use patent on Lyrica, but no composition patent on it. That means anyone is free to make the drug. You can't really stop a doctor from using a drug for a certain disease if it's freely available.
You know what I cannot live with? My genes being owned by somebody else.